RecruitingPhase 1Phase 2NCT06499350

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

A Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of AXL Inhibitor FC084CSA Tablets in Combination With Tislelizumab in the Treatment of Advanced Malignant Solid Tumors

Sponsor

FindCure Biosciences (ZhongShan) Co., Ltd.

Enrollment

33 participants

Start Date

Nov 13, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced malignant solid tumors

Summary

The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria7

Aged 18 to 75 years old male and female.
Phase Ib: Patients with histologically or cytologically diagnosed solid tumors who have failed standard therapy; Phase IIa: Patients with histologically or cytologically confirmed stage IIIB/IIIC and stage IV NSCLC which surgery or radiotherapy cannot be performed.
No known sensitizing mutations or other actionable oncogenes with approved therapies if available.
Prior PD-1/PD-L1 inhibitor combined with platinum-containing therapy failed;
According to RECIST 1.1, there is at least one measurable lesion.
ECOG performance status 0-1.
Major organs are functioning well.

Exclusion Criteria7

Not recovered from the adverse reactions caused by previous anti-tumor treatments (≥CTCAE grade 1).
Received anti-tumor therapy within 4 weeks before enrollment.
Participated in other clinical trials within 4 weeks before enrollment and used clinical investigational drugs during this period.
Have undergone surgery within 4 weeks before enrollment, and the investigator believes that the patient's state has not recovered to the point where the study can be started.
Patients with ascites (ascites), pleural effusion (pleural effusion) or pericardial effusion that cannot be controlled by drainage or other methods.
Central nervous system metastases with clinical symptoms.
With any situations that the researcher considers inappropriate to participate in this research.